Haleos LabsNSE:HALEOSLABS -0.50%72 ROA % is 0.38% as of Mar. 2026, which is 92% below its 10-year median of 4.49. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 72/100 and a GF Value™ of ₹1,123.78 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,411 Biotechnology companies, Haleos Labs ranks better than 86.89% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Haleos Labs's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹17 Mil.
Haleos Labs's average Total Assets over the quarter that ended in Mar. 2026 was ₹4,544 Mil. Therefore, Haleos Labs's annualized ROA % for the quarter that ended in Mar. 2026 was 0.38%.
The historical rank and industry rank for Haleos Labs's ROA % or its related term are showing as below:
NSE:HALEOSLABS'
s ROA % Range Over the Past 10 Years
Min: 2.31 Med: 4.49 Max: 8
Current: 4.19
During the past 11 years, Haleos Labs's highest ROA % was 8.00%. The lowest was 2.31%. And the median was 4.49%.
NSE:HALEOSLABS's ROA % is ranked better than 86.89% of 1411
companies
in the Biotechnology industry
Industry Median: -32.67
vs NSE:HALEOSLABS: 4.19
Haleos Labs (NSE:HALEOSLABS) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Haleos Labs ROA % Related Terms
Haleos Labs ROA % Historical Data
* Premium members only.
The historical data trend for Haleos Labs's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:HALEOSLABS vs VRTX, REGN, ALNY: ROA % Comparison
For the Biotechnology subindustry, Haleos Labs's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleos Labs ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Haleos Labs's ROA % distribution charts can be found below:
* The bar in red indicates where Haleos Labs's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Haleos Labs (NSE:HALEOSLABS) has a ROA % of 0.38% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Haleos Labs and its competitors. This is 92% below median its historical median of 4.49. Over the past decade, Haleos Labs' ROA % has ranged from 2.31 to 8.00. According to the industry distribution chart, Haleos Labs ranks #185 out of 1411 companies in the Biotechnology industry, placing it in the top 13.1%.
Is Haleos Labs' ROA % too high?
Haleos Labs' current ROA % of 0.38% is 92% below median its 10-year median of 4.49. Over the past 10 years, this metric has ranged from a low of 2.31 to a high of 8.00. Based on the distribution chart, Haleos Labs ranks #185 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #185 out of 1411 companies for ROA %. This places Haleos Labs in the top 13% of its industry — outperforming the majority of peers. Historically, Haleos Labs' own ROA % has ranged from 2.31 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Haleos Labs and its competitors. Haleos Labs's current ROA % is 0.38%, which is 92% below median its own 10-year median of 4.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,123.78, compared to a current price of ₹1,612.30 — trading 43.5% above its estimated fair value. The current ROA % is 0.38%, which is 92% below median its 10-year median of 4.49. Haleos Labs' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current ROA % is 0.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?
Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued.
The current stock price of ₹1,612.30 is trading 43.5% above its estimated GF Value™ of ₹1,123.78.
GuruFocus considers Haleos Labs to be Significantly Overvalued.
Key valuation signals for NSE:HALEOSLABS:
ROA %: 0.38% (92% below median its 10-year median of 4.49)
GF Value™: ₹1,123.78 vs. price of ₹1,612.30 (43.5% above fair value)
No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score
Get the complete analysis for NSE:HALEOSLABS
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HALEOSLABS has been successfully added to your 
